# Anaheim Bio

> Preclinical biotech developing ANA-1 candidate treatment for calcium pyrophosphate deposition disease (CPPD).

## Why it is interesting

Nov 5 2026 €40M Series A follows a spinout from Alesta Therapeutics; aims to enter human clinical trials in 2027. No clinical efficacy or approval established.

## Profile

- **Latest funding:** Series A — €40M (November 5, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** Not publicly disclosed
- **Stage:** series-a
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-11-06
- **Latest funding investors:** Droia Ventures, Frazier Life Sciences, RTW, Novartis Venture Fund, RV Invest, Thuja Capital

## Funding history

- Series A · €40M · November 5, 2026
  Source: https://www.prnewswire.co.uk/news-releases/anaheim-bio-launches-with-40-million-series-a-financing-to-advance-ana-1-for-calcium-pyrophosphate-deposition-disease-into-the-clinic-302929917.html

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 6, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/anaheim-bio